


## SUPPLEMENTARY MATERIAL

**Supplementary table 1.** Characteristics of RA patients. All RA patients were female, ACPA+ and former smokers.


<i>RA patient</i>	<i>Age</i>	<i>BMI</i>	<i>Months on MTX</i>	<i>DAS28 at baseline</i>	<i>DAS28 at follow up</i>	$\Delta$ <i>DAS28</i>	<i>CRP at baseline</i>	<i>CRP at follow up</i>	<i>ESR at baseline</i>	<i>ESR at follow up</i>	<i>Response to MTX</i>
1	72	24.8	2.5	6.7	2.6	4.1	112	12	74	22	R
2	60	29.4	3.3	4.7	3.2	1.5	17	4	41	26	R
3	50	28.2	3.9	4.3	2.1	2.2	2	1	42	14	R
4	62	25.9	3.0	5.6	2.9	2.7	7	8	37	23	R
5	68	23.8	2.7	4.3	4.5	-0.2	3	18	29	56	NR
6	65	27.4	3.2	5.1	5.2	-0.1	23	19	47	42	NR
7	66	25.2	3.4	4.5	4.5	0	4	9	20	21	NR
8	50	29.8	4	4.2	4.1	0.1	19	21	17	22	NR

a)


Size Box Plot - All - Capture Probe: CD63



Size Box Plot - All - Capture Probe: CD81




Size Box Plot - All - Capture Probe: CD9




b)


Size Box Plot - All - Capture Probe: CD63



Size Box Plot - All - Capture Probe: CD81




Size Box Plot - All - Capture Probe: CD9




c)


Size Box Plot - All - Capture Probe: CD63




Size Box Plot - All - Capture Probe: CD81



Size Box Plot - All - Capture Probe: CD9



**Supplementary figure 1. Size distribution of sEVs captured by the ExoView chip. a) MTX-responders, b) MTX-non-responders and c) healthy controls.**



**Supplementary figure 2. Phenotypic analysis of triple positive sEVs captured by anti-CD9.** The average colocalization percent (ACP) sample mean of the two study phenotypes were compared using Welch's two samples t-test.